AQR Arbitrage’s Silexion Therapeutics Warrant SLXNW Stock Holding History

AQR Arbitrage’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,313	Closed	-$390	–	511
2024 Q3	$390	Buy	+12,313	New	+$713	﹤0.01%	531

Other funds holding SLXNW

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AQR Arbitrage's SLXNW Position: Q4 2024 in Review

AQR Arbitrage sold out of Silexion Therapeutics Warrant (SLXNW) in Q4 2024, closing a stake of 12,313 shares — an estimated $390 sold.

AQR Arbitrage first reported a position in SLXNW in Q3 2024 and held it in 1 quarter. The position peaked at $390 in Q3 2024. 26 funds tracked by Wall St. Rank hold SLXNW as of Q4 2024.

AQR Arbitrage reported no remaining Silexion Therapeutics Warrant position as of Q4 2024 after selling out during the quarter.
AQR Arbitrage sold 12,313 Silexion Therapeutics Warrant shares in Q4 2024, an estimated $390.
AQR Arbitrage first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 1 quarter.
AQR Arbitrage's Silexion Therapeutics Warrant position peaked at $390 in Q3 2024.
26 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q4 2024.

Based on AQR Arbitrage's 13F filing for Q4 2024, filed 14 Feb 2025.